Aethlon Medical, Inc. (AEMD)
NASDAQ: AEMD · Real-Time Price · USD
0.4100
+0.0440 (12.02%)
At close: May 12, 2025, 4:00 PM
0.4195
+0.0095 (2.32%)
After-hours: May 12, 2025, 7:10 PM EDT
Company Description
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States.
It develops Hemopurifier, a clinical-stage immunotherapeutic device for cancer and life-threatening viral infections and use in organ transplantation.
The company was founded in 1984 and is based in San Diego, California.
Aethlon Medical, Inc.
| Country | United States |
| Founded | 1984 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 14 |
| CEO | James Frakes |
Contact Details
Address: 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 United States | |
| Phone | 619 941 0360 |
| Website | aethlonmedical.com |
Stock Details
| Ticker Symbol | AEMD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0000882291 |
| CUSIP Number | 00808Y307 |
| ISIN Number | US00808Y4061 |
| Employer ID | 13-3632859 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| James B. Frakes M.B.A. | Chief Executive Officer, Chief Financial Officer, Secretary and Director |
| Guy F. Cipriani BS (Eng.), MBA | Senior Vice President and Chief Operating Officer |
| Dr. Steven P. LaRosa M.D. | Chief Medical Officer |
| Michele Bombardiere | Vice President and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 17, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 12, 2025 | 10-Q | Quarterly Report |
| Feb 12, 2025 | 8-K | Current Report |
| Jan 30, 2025 | 1-A/A | Filing |
| Jan 8, 2025 | 8-K | Current Report |
| Dec 27, 2024 | 1-A | Filing |
| Dec 20, 2024 | 8-K | Current Report |